Bicycle Therapeutics plc Share Price & Technical Analysis
BCYC · $4.55 (+2.25%)
Healthcare / Biotechnology
$4.55
+2.25%
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide p…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-2% return in May, 3% avg return in past 3 year May month.
-41% return in 2026, -31% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -11% | -18% | 0% | -2% | – | – | – | – | – | – | – | -41% |
| 25 | -4% | -16% | -22% | 2% | -6% | -17% | 23% | -11% | 5% | 5% | -6% | -4% | -49% |
| 24 | -3% | 43% | -2% | -5% | -6% | -11% | 21% | -13% | 5% | 4% | -12% | -31% | -11% |
| 23 | -8% | -18% | -6% | -7% | 22% | 7% | -4% | -11% | -8% | -24% | -3% | 27% | -34% |
| 22 | -20% | -2% | -5% | -46% | -32% | 5% | 41% | 12% | -10% | 6% | 16% | 2% | -33% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$321.12M
P/E ratio
—
52W high
$9.36
52W low
$4.24
Volume
2,99,685
Beta
1.65
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Bicycle Therapeutics plc share price today?
- Bicycle Therapeutics plc (BCYC) last traded around $4.55 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BCYC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BCYC. Download the app for real-time alerts.
- How can I analyze Bicycle Therapeutics plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.